[go: up one dir, main page]

BRPI0820440A2 - Inibidores aldh-2 no tratamento de desordens psiquiátricas - Google Patents

Inibidores aldh-2 no tratamento de desordens psiquiátricas

Info

Publication number
BRPI0820440A2
BRPI0820440A2 BRPI0820440-3A BRPI0820440A BRPI0820440A2 BR PI0820440 A2 BRPI0820440 A2 BR PI0820440A2 BR PI0820440 A BRPI0820440 A BR PI0820440A BR PI0820440 A2 BRPI0820440 A2 BR PI0820440A2
Authority
BR
Brazil
Prior art keywords
aldh
inhibitors
treatment
psychiatric disorders
psychiatric
Prior art date
Application number
BRPI0820440-3A
Other languages
English (en)
Inventor
Ivan Diamond
David Overstreet
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of BRPI0820440A2 publication Critical patent/BRPI0820440A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
BRPI0820440-3A 2007-11-06 2008-11-06 Inibidores aldh-2 no tratamento de desordens psiquiátricas BRPI0820440A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98591107P 2007-11-06 2007-11-06
PCT/US2008/082643 WO2009061924A2 (en) 2007-11-06 2008-11-06 Aldh-2 inhibitors in the treatment of psychiatric disorders

Publications (1)

Publication Number Publication Date
BRPI0820440A2 true BRPI0820440A2 (pt) 2015-05-26

Family

ID=40512184

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820440-3A BRPI0820440A2 (pt) 2007-11-06 2008-11-06 Inibidores aldh-2 no tratamento de desordens psiquiátricas

Country Status (12)

Country Link
US (1) US20090124672A1 (pt)
EP (1) EP2231149A2 (pt)
JP (1) JP2011503095A (pt)
KR (1) KR20100097675A (pt)
CN (1) CN101917987A (pt)
AU (1) AU2008323953A1 (pt)
BR (1) BRPI0820440A2 (pt)
CA (1) CA2704981A1 (pt)
IL (1) IL205578A0 (pt)
MX (1) MX2010005047A (pt)
RU (1) RU2010122970A (pt)
WO (1) WO2009061924A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2653056A1 (en) * 2006-07-27 2008-01-31 Cv Therapeutics, Inc. Aldh-2 inhibitors in the treatment of addiction
US20080207610A1 (en) * 2006-07-27 2008-08-28 Jeff Zablocki Aldh-2 inhibitors in the treatment of addiction
US8158810B2 (en) * 2006-07-27 2012-04-17 Gilead Sciences, Inc. ALDH-2 inhibitors in the treatment of addiction
CN101925590A (zh) * 2008-01-24 2010-12-22 吉利德帕洛阿尔托股份有限公司 治疗成瘾的aldh-2抑制剂
WO2009100380A1 (en) * 2008-02-06 2009-08-13 Cv Therapeutics, Inc. Use of ranolazine for treating pain
US9063420B2 (en) 2013-07-16 2015-06-23 Rohm And Haas Electronic Materials Llc Photoresist composition, coated substrate, and method of forming electronic device
US9410016B2 (en) 2013-07-16 2016-08-09 Dow Global Technologies Llc Aromatic polyacetals and articles comprising them
US8962779B2 (en) 2013-07-16 2015-02-24 Dow Global Technologies Llc Method of forming polyaryl polymers
US8933239B1 (en) 2013-07-16 2015-01-13 Dow Global Technologies Llc Bis(aryl)acetal compounds
JP7618230B2 (ja) * 2019-07-25 2025-01-21 学校法人東京理科大学 精神・神経系の疾患又は症状を治療し、予防し又は改善する剤
US12018009B2 (en) 2022-06-14 2024-06-25 Amygdala Neurosciences, Inc. ALDH-2 inhibitor compounds and methods of use
WO2023244563A1 (en) 2022-06-14 2023-12-21 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204369A (en) * 1991-07-01 1993-04-20 The Endowment For Research In Human Biology Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse
US6255497B1 (en) * 1997-04-29 2001-07-03 The Endowment For Research In Human Biology, Inc. Method for the inhibition of ALDH-I useful in the treatment of alcohol dependence or alcohol abuse
AU3899199A (en) * 1998-05-12 1999-11-29 Endowment for Research in Human Biology, Inc., The Methods and assays useful in the treatment of alcohol dependence or alcohol abuse
AU2001266223A1 (en) * 2000-06-30 2002-01-14 Cardiff & Vale National Health Service Trust Methods and compositions for the treatment of alcoholism and alcohol dependence
WO2004001058A2 (en) * 2001-05-04 2003-12-31 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
CN1671373A (zh) * 2002-06-27 2005-09-21 人类生物研究基金公司 用于抑制aldh的化合物
CA2653056A1 (en) * 2006-07-27 2008-01-31 Cv Therapeutics, Inc. Aldh-2 inhibitors in the treatment of addiction
US20080207610A1 (en) * 2006-07-27 2008-08-28 Jeff Zablocki Aldh-2 inhibitors in the treatment of addiction
CA2682207A1 (en) * 2007-04-05 2008-10-16 Cv Therapeutics, Inc. Quinazolinone derivatives as aldh-2 inhibitors

Also Published As

Publication number Publication date
RU2010122970A (ru) 2011-12-20
JP2011503095A (ja) 2011-01-27
EP2231149A2 (en) 2010-09-29
WO2009061924A3 (en) 2009-07-09
WO2009061924A2 (en) 2009-05-14
KR20100097675A (ko) 2010-09-03
IL205578A0 (en) 2010-11-30
AU2008323953A1 (en) 2009-05-14
MX2010005047A (es) 2010-07-28
CN101917987A (zh) 2010-12-15
US20090124672A1 (en) 2009-05-14
CA2704981A1 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
BRPI0820440A2 (pt) Inibidores aldh-2 no tratamento de desordens psiquiátricas
SMP200900085B (it) 3-imidazolil-indoli per il trattamento di malattieproliferative.
LT2894165T (lt) Būdai ir kompozicijos, skirti su komplementu susijusių sutrikimų gydymui
IL187168A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
HUE038588T2 (hu) IL-22 mikrobiális rendellenességek kezelésében történõ alkalmazásra
AP2011005672A0 (en) Pyrazolopyrimidines and their use for the treatment of CNS disorders.
GB2467710B (en) Methods for treating social disorders
DE602006019395D1 (de) Media-behandlungseinrichtung
ZA201001264B (en) 1-amino-alkylcycohxane derivatives for the treatment of cochleat tinnitus
EP2139475A4 (en) USE OF PDE7 INHIBITORS IN THE TREATMENT OF
DK2173831T3 (da) Brøndbehandling
HK1247943A1 (zh) 發育相關疾病的治療
BRPI0808043A2 (pt) Compostos tricíclicos úteis no tratamento de distúrbios de ferro.
BRPI0818170A2 (pt) 5-cianotienopiridinas para o tratamento de tumores.
BRPI0822129A2 (pt) Inibidores de aldh-2c no tratamento de vício.
BRPI0821026A2 (pt) Derivados de alfa-minoamidas úteis no tratamento de transtornos psiquiátricos
BRPI0816791A2 (pt) tratamento de sintomas vasomotores.
FI20051207A0 (fi) Selän hoitolaite
BRPI0714307A2 (pt) Uso de benzamidas trifluormetil-substituídas no tratamento de distúrbios neurológicos
AT503071A3 (de) Pflanzenkläranlage
FI6726U1 (fi) Hieromalaite
GB0602857D0 (en) The treatment of sialorrhoea
BRPI0716580A2 (pt) Tratamento de distúrbios fibrosantes
BRPI0820437A2 (pt) Método de tratamento de artrite.
DK1909800T3 (da) Acylglycerophospholipider til behandling af symptomer i forbindelse med cancer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.